2026-04-14T04:12:12Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4704472024-11-04T06:25:35Zcom_2072_98col_2072_378192

Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations : a pooled analysis from four clinical trials Allan, John N. Shanafelt, Tait Wiestner, Adrian Moreno, Carol O'Brien, Susan M. Li, Jianling Krigsfeld, Gabriel Dean, James P. Ahn, Inhye E. Universitat Autònoma de Barcelona Chronic lymphocytic leukaemia Del(17p) First-line Ibrutinib TP53 mutation TP53 aberrations [del(17p) or TP53 mutation] predict poor survival with chemoimmunotherapy in patients with chronic lymphocytic leukaemia (CLL). We evaluated long-term efficacy and safety of first-line ibrutinib-based therapy in patients with CLL bearing TP53 aberrations in a pooled analysis across four studies: PCYC-1122e, RESONATE-2 (PCYC-1115/16), iLLUMINATE (PCYC-1130) and ECOG-ACRIN E1912. The pooled analysis included 89 patients with TP53 aberrations receiving first-line treatment with single-agent ibrutinib (n = 45) or ibrutinib in combination with an anti-CD20 antibody (n = 44). All 89 patients had del(17p) (53% of 89 patients) and/or TP53 mutation (91% of 58 patients with TP53 sequencing results available). With a median follow-up of 49·8 months (range, 0·1-95·9), median progression-free survival was not reached. Progression-free survival rate and overall survival rate estimates at four years were 79% and 88%, respectively. Overall response rate was 93%, including complete response in 39% of patients. No new safety signals were identified in this analysis. Forty-six percent of patients remained on ibrutinib treatment at last follow-up. With median follow-up of four years (up to eight years), results from this large, pooled, multi-study data set suggest promising long-term outcomes of first-line ibrutinib-based therapy in patients with TP53 aberrations. Registered at ClinicalTrials.gov (NCT01500733, NCT01722487, NCT02264574 and NCT02048813). 2021 Article https://ddd.uab.cat/record/282983 urn:10.1111/bjh.17984 urn:oai:ddd.uab.cat:282983 urn:pmcid:PMC9299890 urn:pmc-uid:9299890 urn:pmid:34865212 urn:oai:pubmedcentral.nih.gov:9299890 urn:articleid:13652141v196p947 http://hdl.handle.net/2072/470447 eng British Journal of Haematology ; Vol. 196 (december 2021), p. 947-953 open access Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. https://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf